AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06088381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Observation
Description: Patients on the experimental arm will be under observation only.
Study NCT06088381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation per Standard of Care
Description: The low-risk group of patients will be observed per standard of care.
Study NCT04855721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06088381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment per Standard of Care
Description: The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
Study NCT06088381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA test (ctDNA test)
Description: Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
Study NCT06219928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
Study NCT06219928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Group
Description: After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
Study NCT06219928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
Study NCT06672731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: REMS: Radiofrequency Echographic Multi Spectrometry
Description: it is a non invasive ultrasonographic evaluation of bone and muscle quality
Study NCT06242509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biological samples
Description: Plasma sampling ans stool sampling~* at inclusion~* at 1 month~* at 3 months~* at progression within the 3 months
Study NCT06482918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-assisted top-down or bottom-up cognitive remediation using tablets
Study NCT06672731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: REMS: Radiofrequency Echographic Multi Spectrometry
Description: it is a non invasive ultrasonographic evaluation of bone and muscle quality
Study NCT05099666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
Study NCT05241314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After Deployment Adaptive Parenting Tools (ADAPT)
Description: A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
Study NCT05099666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Study NCT04768114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetically-Informed RiskProfile
Description: * Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing.
Study NCT04768114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cessation Advice
Description: * Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Study NCT06115031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
Study NCT06115031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
Study NCT05108922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
Study NCT05108922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aducanumab
Description: Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Study NCT05625620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Pulse Current Stimulation
Description: Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
Study NCT05625620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Pulse Current Stimulation
Description: Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study NCT04653532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Programme and Counselling
Description: A 6 month exercise and physical activity programme supported by an exercise specialist
Study NCT04653532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme and Counselling
Description: A 6 month exercise and physical activity programme supported by an exercise specialist
Study NCT04653532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Ignite and App
Description: A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
Study NCT06547840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
Study NCT06039267 — intervention group
Intervention type: OTHER
Intervention: Gut Microbiome Testing
Description: Stool microbiome testing using shotgun metagenomic sequencing
Study NCT04752605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finnish ENGAGE together
Description: Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
Study NCT05099666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Study NCT05190341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg oral
Description: 1 hour before HSG
Study NCT05190341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg oral
Description: 1 hour before HSG
Study NCT06692231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
Study NCT06693622 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient survey
Description: To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
Study NCT06692413 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Users who consent to the study will receive a questionnaire every 3 months
Study NCT05598515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Participants will be asked to eat for only 8 hours out of 24 hours in a day.
Study NCT06693375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
Study NCT06693375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal Magnetomotoric ultrasound (MMUS)
Description: MMUS examination of lymphnodes in rectum
Study NCT06693375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
Study NCT06693375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
Study NCT06693375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
Study NCT06692751 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 2 tubes of 5 mL
Study NCT06692751 — intervention group
Intervention type: PROCEDURE
Intervention: Ophthalmological examination
Description: angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A.
Study NCT06692751 — intervention group
Intervention type: OTHER
Intervention: angina severity questionnaire
Description: at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
Study NCT06715488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI assisted smartphone diagnosis
Description: Patients will examination and clinical photographs for convolutional networks to diagnose inflammatory arthritis
Study NCT06747936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2281
Description: PO, Once daily, 8weeks
Study NCT06747936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2281
Description: PO, Once daily, 8weeks
Study NCT06747936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2282
Description: PO, Once daily, 8weeks
Study NCT06747936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-2282
Description: PO, Once daily, 8weeks
Study NCT06747221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: SAIA is a 5-step implementation strategy that is repeated every 4-6 weeks for continuous quality improvement. It will be implemented by Kenyan public health workforce and frontline clinical care personnel to systematically identify and address bottlenecks to develop and implement solutions to delivery of HIV Testing Services during emergency department (ED) interactions.~Step 1: Understanding the cascade of ED patient flow from triage through care conclusion with focus on HTS opportunities. This will support identification of bottlenecks where patients are missed and provides data on potential increases in efficiency if misses are addressed.~Step 2: Use process mapping to identify modifiable bottlenecks.~Step 3: Define and implement workflow adaptations to mitigate modifiable bottlenecks.~Step 4: Monitor changes in performance.~Step 5: Repeat the analysis and improvement cycle (steps 1-4).
Study NCT06746311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-101
Description: Single dose of HT-101 administered subcutaneously.
Study NCT05899049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study NCT06746311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-101
Description: Multiple dose of HT-101 administered subcutaneously.
Study NCT06746311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, containing no active ingredient, administered subcutaneouly
Study NCT05590949 — intervention group
Intervention type: OTHER
Intervention: Physical Evaluation
Description: Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
Study NCT05590949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry scans
Description: Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
Study NCT05590949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trabecular Bone Score
Description: TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
Study NCT05899049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study NCT05601505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circulating tumor DNA
Description: This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
Study NCT05872438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal, Oral and anal sampling
Description: The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
Study NCT05149768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
Study NCT06564402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Rehearsal
Description: After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
Study NCT04700124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
Study NCT04700124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (EV)
Description: 1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
Study NCT06564402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Rehearsal
Description: After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
Study NCT06564402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
Study NCT06564402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
Study NCT06638164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
Study NCT06638164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
Study NCT04700124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RC + PLND
Description: Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
Study NCT05899049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet
Study NCT05899049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
Study NCT05899049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study NCT05899049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study NCT06292702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Burch colposuspension
Description: Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
Study NCT05792462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
Study NCT06292702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Burch colposuspension
Description: Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
Study NCT04700124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RC + PLND
Description: Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
Study NCT04700124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)